Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

### 144: Filer Information

Filer CIK 0001488668
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

**Submission Contact Information** 

Name

Phone

E-Mail Address

#### 144: Issuer Information

Name of Issuer Black Diamond Therapeutics Inc

SEC File Number 001-39200
One Main Street

Floor 14

Address of Issuer Cambridge

MASSACHUSETTS

02142

Phone 6172520848

Name of Person for Whose Account the Securities are To Be Sold

David Epstein

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Former Employer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	50000	250000	56252794	06/28/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Date you Nature of Name of Is Date Amount of Date of Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	Acquired	Securities Acquired	Payment	Payment *
Class A	09/19/2016 F	Counder Shares	David Epstein		421665	09/19/2016 Ca	sh

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Securities Sold	<b>Gross Proceeds</b>
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/12/2024 62528	383921
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/13/2024 70853	435745
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/14/2024 24621	148957
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/18/2024 2951	16082
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/20/2024 20143	101117
Leah Wu 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/20/2024 20268	101745
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/21/2024 743	3715
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/24/2024 6011	30175
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/26/2024 9647	45340
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/27/2024 38003	178614
David Epstein 56 Pine Street Belmont MA 02478	Black Diamond Therapeutics Inc	06/28/2024 2350	8695

# 144: Remarks and Signature

Remarks

Date of Notice 06/28/2024 **ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ UBS Financial Services Inc, as attorney-in-fact for David Epstein

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)